» Articles » PMID: 31750030

Consensus-based Care Recommendations for Congenital and Childhood-onset Myotonic Dystrophy Type 1

Abstract

Purpose Of Review: Myotonic dystrophy type 1 is a multisystemic disorder caused by a noncoding triplet repeat. The age of onset is variable across the lifespan, but in its most severe form, the symptoms appear at birth (congenital myotonic dystrophy) or in the pediatric age range (childhood-onset myotonic dystrophy). These children have a range of disabilities that reduce the lifespan and cause significant morbidity. Currently, there are no agreed upon recommendations for caring for these children.

Recent Findings: The Myotonic Dystrophy Foundation recruited 11 international clinicians who are experienced with congenital and childhood-onset myotonic dystrophy to create consensus-based care recommendations. The experts used a 2-step methodology using elements of the single text procedure and nominal group technique. Completion of this process has led to the development of clinical care recommendations for this population.

Summary: Children with myotonic dystrophy often require monitoring and interventions to improve the lifespan and quality of life. The resulting recommendations are intended to standardize and improve the care of children with myotonic dystrophy.

Citing Articles

Benchmarking nanopore sequencing and rapid genomics feasibility: validation at a quaternary hospital in New Zealand.

Nyaga D, Tsai P, Gebbie C, Phua H, Yap P, Le Quesne Stabej P NPJ Genom Med. 2024; 9(1):57.

PMID: 39516456 PMC: 11549486. DOI: 10.1038/s41525-024-00445-5.


Fetal Brain MRI Findings in Myotonic Dystrophy and Considerations for Prenatal Genetic Testing.

Shear M, Penon-Portmann M, Shieh J, Glenn O, Thiet M, Chetty S Neurol Genet. 2024; 10(6):e200171.

PMID: 39444647 PMC: 11498903. DOI: 10.1212/NXG.0000000000200171.


Association between Reported Sleep Disorders and Behavioral Issues in Children with Myotonic Dystrophy Type 1-Results from a Retrospective Analysis in Italy.

Trucco F, Lizio A, Roma E, Di Bari A, Salmin F, Albamonte E J Clin Med. 2024; 13(18).

PMID: 39336946 PMC: 11432637. DOI: 10.3390/jcm13185459.


Parental diagnostic delay and developmental outcomes in congenital and childhood-onset myotonic dystrophy type 1.

Trucco F, Albamonte E, Pane M, Ricci F, DAmico A, Astrea G Dev Med Child Neurol. 2024; 67(3):365-373.

PMID: 39231278 PMC: 11794672. DOI: 10.1111/dmcn.16079.


Diagnosis and Management of Myotonic Dystrophy Type 1.

Hartman J, Patki T, Johnson N JAMA. 2024; 331(14):1227-1228.

PMID: 38466298 PMC: 11618391. DOI: 10.1001/jama.2024.2511.


References
1.
Yao X, Yang Y, Cui L, Zhao K, Zhang Z, Peng L . Subtypes of irritable bowel syndrome on Rome III criteria: a multicenter study. J Gastroenterol Hepatol. 2011; 27(4):760-5. DOI: 10.1111/j.1440-1746.2011.06930.x. View

2.
Gagnon C, Heatwole C, Hebert L, Hogrel J, Laberge L, Leone M . Report of the third outcome measures in myotonic dystrophy type 1 (OMMYD-3) international workshop Paris, France, June 8, 2015. J Neuromuscul Dis. 2018; 5(4):523-537. DOI: 10.3233/JND-180329. View

3.
Campbell C, Sherlock R, Jacob P, Blayney M . Congenital myotonic dystrophy: assisted ventilation duration and outcome. Pediatrics. 2004; 113(4):811-6. DOI: 10.1542/peds.113.4.811. View

4.
Johnson N, Ekstrom A, Campbell C, Hung M, Adams H, Chen W . Parent-reported multi-national study of the impact of congenital and childhood onset myotonic dystrophy. Dev Med Child Neurol. 2015; 58(7):698-705. PMC: 4848162. DOI: 10.1111/dmcn.12948. View

5.
Brook J, McCurrach M, Harley H, Buckler A, Church D, Aburatani H . Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member. Cell. 1992; 68(4):799-808. DOI: 10.1016/0092-8674(92)90154-5. View